Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
Dean Follmann, Jonathan Fintzi, Michael P. Fay, Holly E. Janes, Lindsey Baden, Hana El Sahly, Thomas R. Fleming, Devan V. Mehrotra, Lindsay N. Carpp, Michal Juraska, David Benkeser, Deborah Donnell, Youyi Fong, Shu Han, Ian Hirsch, Ying Huang, Yunda Huang, Ollivier Hyrien, Alex Luedtke, Marco Carone, Martha Nason, An Vandebosch, Honghong Zhou, Iksung Cho, Erin Gabriel, James G. Kublin, Myron S. Cohen, Lawrence Corey, Peter B. Gilbert, Kathleen M. Neuzil
doi: https://doi.org/10.1101/2020.12.14.20248137
Dean Follmann
1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
PhDJonathan Fintzi
1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
PhDMichael P. Fay
1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
PhDHolly E. Janes
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
PhDLindsey Baden
3Brigham and Women’s Hospital, Boston, MA, USA
MDHana El Sahly
3aBaylor College of Medicine, Houston, TX, USA
MDThomas R. Fleming
4Department of Biostatistics, University of Washington, Seattle, WA, USA
PhDDevan V. Mehrotra
5Biostatistics and Research Decision Sciences, Merck & Co., Inc., North Wales, PA, USA
PhDLindsay N. Carpp
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
PhDMichal Juraska
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
PhDDavid Benkeser
6Rollins School of Public Health, Emory University, Atlanta, GA, USA
PhDDeborah Donnell
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
PhDYouyi Fong
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
PhDShu Han
7Moderna, Inc., Cambridge, MA, USA
PhDIan Hirsch
8Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
PhDYing Huang
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
PhDYunda Huang
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
PhDOllivier Hyrien
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
PhDAlex Luedtke
9Department of Statistics, University of Washington, Seattle, WA, USA
PhDMarco Carone
4Department of Biostatistics, University of Washington, Seattle, WA, USA
PhDMartha Nason
1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
PhDAn Vandebosch
10Janssen R&D, Janssen Pharmaceuticals NV, Beerse, Belgium
PhDHonghong Zhou
7Moderna, Inc., Cambridge, MA, USA
PhDIksung Cho
11Biostatistics, Novavax, Inc., Gaithersburg, MD, USA
MSErin Gabriel
12Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden
PhDJames G. Kublin
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
MDMyron S. Cohen
13Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA
MDLawrence Corey
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
14Departments of Medicine and Lab Medicine, University of Washington, Seattle, WA, USA
MDPeter B. Gilbert
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
4Department of Biostatistics, University of Washington, Seattle, WA, USA
PhDKathleen M. Neuzil
15University of Maryland School of Medicine, Baltimore, MD, USA
MDArticle usage
Posted December 14, 2020.
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
Dean Follmann, Jonathan Fintzi, Michael P. Fay, Holly E. Janes, Lindsey Baden, Hana El Sahly, Thomas R. Fleming, Devan V. Mehrotra, Lindsay N. Carpp, Michal Juraska, David Benkeser, Deborah Donnell, Youyi Fong, Shu Han, Ian Hirsch, Ying Huang, Yunda Huang, Ollivier Hyrien, Alex Luedtke, Marco Carone, Martha Nason, An Vandebosch, Honghong Zhou, Iksung Cho, Erin Gabriel, James G. Kublin, Myron S. Cohen, Lawrence Corey, Peter B. Gilbert, Kathleen M. Neuzil
medRxiv 2020.12.14.20248137; doi: https://doi.org/10.1101/2020.12.14.20248137
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
Dean Follmann, Jonathan Fintzi, Michael P. Fay, Holly E. Janes, Lindsey Baden, Hana El Sahly, Thomas R. Fleming, Devan V. Mehrotra, Lindsay N. Carpp, Michal Juraska, David Benkeser, Deborah Donnell, Youyi Fong, Shu Han, Ian Hirsch, Ying Huang, Yunda Huang, Ollivier Hyrien, Alex Luedtke, Marco Carone, Martha Nason, An Vandebosch, Honghong Zhou, Iksung Cho, Erin Gabriel, James G. Kublin, Myron S. Cohen, Lawrence Corey, Peter B. Gilbert, Kathleen M. Neuzil
medRxiv 2020.12.14.20248137; doi: https://doi.org/10.1101/2020.12.14.20248137
Subject Area
Subject Areas
- Addiction Medicine (405)
- Allergy and Immunology (718)
- Anesthesia (210)
- Cardiovascular Medicine (2997)
- Dermatology (256)
- Emergency Medicine (448)
- Epidemiology (12894)
- Forensic Medicine (12)
- Gastroenterology (840)
- Genetic and Genomic Medicine (4692)
- Geriatric Medicine (432)
- Health Economics (740)
- Health Informatics (2982)
- Health Policy (1081)
- Hematology (398)
- HIV/AIDS (942)
- Medical Education (439)
- Medical Ethics (116)
- Nephrology (481)
- Neurology (4482)
- Nursing (239)
- Nutrition (656)
- Oncology (2327)
- Ophthalmology (659)
- Orthopedics (262)
- Otolaryngology (330)
- Pain Medicine (289)
- Palliative Medicine (85)
- Pathology (506)
- Pediatrics (1217)
- Primary Care Research (509)
- Public and Global Health (7069)
- Radiology and Imaging (1570)
- Respiratory Medicine (932)
- Rheumatology (454)
- Sports Medicine (390)
- Surgery (496)
- Toxicology (62)
- Transplantation (214)
- Urology (186)